Resources

Publications

09/09/2022
- Oncology
Safety, Tolerability and Efficacy of Agonist Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti PD-1 (Nivolumab) in Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
09/06/2022
- Oncology
Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options
ESMO 2022
09/06/2022
- Oncology
BRAF Mutations and Fusions in a Real-World Cohort of NSCLC Patients
ESMO 2022
09/06/2022
- Oncology
The Genomic Landscape of Small Cell Lung Cancer in Never Smoking Patients
ESMO 2022
08/03/2022
- Oncology
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy
Journal of the National Cancer Institute
07/26/2022
- Oncology
Comparison of the Tumor Immune Microenvironment and Checkpoint Blockade Biomarkers Between Stage III and IV Non-small Cell Lung Cancer
Cancer Immunology, Immunotherapy, Tempus-authored
07/13/2022
- Oncology
Integration of Tumor Extrinsic and Intrinsic Features Associates With Immunotherapy Response in Non-small Cell Lung Cancer
Nature Communications, Tempus-authored
07/02/2022
- Oncology
Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)
ESMO World Congress on Gastrointestinal Cancer 2022
06/28/2022
- Oncology
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
Cancers
06/16/2022
- Oncology
Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First Line Use
Journal of Medical Economics, Tempus-authored

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69